How Chard was paid
$5.6M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Other | Total |
|---|---|---|---|---|
| Daniel R. ChardChairman & Chief Executive Officer | $1,000,000 | $4,567,664 | $16,886 | $5,584,551 |
| James P. MaloneyChief Financial Officer | $527,085 | $700,427 | $16,403 | $1,428,396 |
| Nicholas M. JohnsonChief Field Operations Officer | $440,352 | $585,163 | $15,980 | $1,195,619 |
| Anthony E. TyreeFormer Chief Business Operations Officer | $415,873 | $162,194 | $761,097 | $1,484,720 |
| Jason L. GrovesChief Legal Officer & Corporate Secretary | $427,781 | $568,465 | $14,483 | $1,160,452 |
What changed and why
- $5.6MDaniel Chard received a total compensation of $5,584,551 for fiscal 2025, a slight decrease from the prior year.
- Medifast advanced a strategic transformation focusing on holistic metabolic health and introduced new coach programs.
- 59.1%Stockholders approved the previous say-on-pay proposal with 59.1% support, prompting continued stockholder outreach.
- Anthony E. Tyree departed as Chief Business Operations Officer effective December 31, 2025, receiving severance benefits.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.